Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319631 | 1.00 | CHRNA7 (0.58) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL3320988 | 1.00 | CHRNA7 (0.58) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL8050322 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL14514757 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL13525452 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL16790664 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL5892019 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL6683718 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL9303682 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL879026 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. | 2017-09-28 | — | — | US | claimed |
| EP-2959902-A1 | USE OF AZABICYCLOALKYL DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | Novartis AG (CH) | 2015-12-30 | — | — | EP | claimed |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| EP-2598135-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Koenig, Gerhard (US) | 2013-06-05 | — | — | EP | claimed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| CN-117679415-A | Glucoamide synthase inhibitors | 建新公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-2945633-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| EP-2945637-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG | 2010-05-20 | — | — | US | disclosed |
| EP-2135609-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1809285-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048294-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885CA12 2331/4885CA1 1049/4885 |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885CA12 1246/4885CA1 777/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CA12 4389/4885CA1 3269/4885 |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CA12 4409/4885CA1 2276/4885 |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | CHRNA7, CHRNA6, CHRNA2 | CHRNA7 1/4885CA12 1795/4885CA1 593/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885CA12 3676/4885CA1 2119/4885 |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CA12 4333/4885CA1 1999/4885 |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | ATXN2, CDR2, ATXN2L | CHRNA7 205/4885CA12 3729/4885CA1 1765/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CA12 2347/4885CA1 1331/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CA12 4389/4885CA1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.